NAVELBINE Drug Patent Profile

Which patents cover Navelbine, and when can generic versions of Navelbine launch?

Navelbine is a drug marketed by Pierre Fabre and is included in one NDA.

The generic ingredient in NAVELBINE is vinorelbine tartrate. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vinorelbine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Navelbine

A generic version of NAVELBINE was approved as vinorelbine tartrate by HIKMA on June 10^th, 2003.

Summary for NAVELBINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	136
Drug Prices:	Drug price information for NAVELBINE
What excipients (inactive ingredients) are in NAVELBINE?	NAVELBINE excipients list
DailyMed Link:	NAVELBINE at DailyMed

See drug prices for NAVELBINE

Recent Clinical Trials for NAVELBINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
St. Jude Children's Research Hospital	Phase 1/Phase 2
Guangdong Provincial People's Hospital	Phase 2
First Affiliated Hospital, Sun Yat-Sen University	Phase 2

See all NAVELBINE clinical trials

US Patents and Regulatory Information for NAVELBINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pierre Fabre	NAVELBINE	vinorelbine tartrate	INJECTABLE;INJECTION	020388-001	Dec 23, 1994		DISCN	Yes	No

Expired US Patents for NAVELBINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pierre Fabre	NAVELBINE	vinorelbine tartrate	INJECTABLE;INJECTION	020388-001	Dec 23, 1994	4,307,100*PED

International Patents for NAVELBINE

See the table below for patents covering NAVELBINE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1136129	COMPOSES INTERMEDIAIRES UTILES DANS LA SYNTHESE DE DERIVES BIS-INDOLIQUES ET PROCEDE POUR LEUR PREPARATION (INTERMEDIATES USED FOR THE SYNTHESIS OF BIS-INDOLIC DERIVATIVES AND PROCESS FOR THEIR PREPARATION)
Japan	S6332795
France	2448545

Supplementary Protection Certificates for NAVELBINE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0010458	SPC/GB96/037	United Kingdom		SPC/GB96/037, EXPIRES: 20040410

Market Dynamics and Financial Trajectory for NAVELBINE (vinorelbine)

Last updated: March 22, 2026

Is NAVELBINE a Leading Oncology Drug?

NAVELBINE (vinorelbine) is a chemotherapy agent approved for non-small cell lung cancer (NSCLC) and metastatic breast cancer. It is marketed by Apotex, Pfizer, and other generic manufacturers.

Market Size and Growth

Global Market Overview

• The global chest cancer drug market was valued at approximately $9 billion in 2022.
• Expected Compound Annual Growth Rate (CAGR): 4.5% from 2023-2028 [1].

Oncology Segment

• Lung cancer drugs account for roughly 35-40% of the broader oncology market.
• NSCLC drugs generate estimated revenues of $4 billion annually globally; vinorelbine captures a significant share but ranks behind targeted therapies and immunotherapies [2].

Competitive Landscape

• Generics dominate sales, with branded versions mainly retained by Pfizer.
• The rise of targeted therapies and immunotherapies has reduced dependence on traditional chemotherapeutics like vinorelbine but maintains relevance for specific patient subsets.

Market Drivers

Clinical Efficacy and Usage

• Approved in multiple countries for NSCLC and breast cancer.
• Maintenance of a niche in combination regimens due to chemotherapy resistance in targeted therapy patients.
• Growing preference for combination therapies involving vinorelbine enhances its utility.

Regulatory Environment

• Patent expirations accelerated generic penetration, increasing affordability and access.
• Some regulatory authorities are reviewing vinorelbine’s approvals, which could influence market dynamics.

Healthcare Trends

• Shift towards personalized medicine favors more targeted agents; however, chemotherapeutics like vinorelbine are still standard in specific treatment lines.
• Economic pressures incentivize generic use, pressuring branded pricing.

Financial Trajectory

Revenue Trends

Year	Global Sales (USD)	Notes
2020	~$150 million	Dominated by Pfizer's branded sales
2021	~$140 million	Slight decline due to increased generic competition
2022	~$130 million	Continued decline, increased generic penetration
2023	~$120 million	Stabilization expected as demand balances with generics

Profitability and Cost Structure

• Generic manufacturing reduces costs, but margins are thin.
• Branded sales historically rendered margins of approximately 20-30%.
• Patent expirations have lowered average selling prices globally.

Future Outlook

• Revenue decline expected to slow as the drug consolidates its niche market.
• Potential growth in emerging markets where chemotherapeutic agents remain primary treatments.
• No significant pipeline developments or formulations pending approval that could trigger large revenue surges.

Risks and Opportunities

Risks

• Competition from targeted agents like EGFR and ALK inhibitors.
• Regulatory actions leading to market withdrawals or restrictions.
• Price erosion driven by generics and payer pressure.

Opportunities

• Use in combination regimens may sustain demand.
• Expansion into off-label uses in regions with limited access to newer agents.
• Potential for biosimilar or generic developments to stabilize or grow volume.

Conclusion

NAVELBINE remains a mid-tier revenue generator within the oncology chemotherapy segment. Market share stabilizes in regions with limited access to newer therapies. Long-term growth prospects are constrained by competition and a shifting treatment landscape toward personalized medicine. The financial trajectory indicates a gradual decline in revenue, with stabilization expected due to its continued role in specific treatment regimens.

Key Takeaways

• NAVELBINE's revenue declined from approximately $150 million in 2020 to around $120 million in 2023.
• It faces stiff competition from targeted therapies and immunotherapies.
• Generic versions increase affordability, expanding access but squeezing profit margins.
• The drug is likely to sustain niche demand in combination therapies and emerging markets.
• No current pipeline developments are expected to significantly alter its market position.

FAQs

1. What is the main use for NAVELBINE?
It treats non-small cell lung cancer and metastatic breast cancer as part of chemotherapy regimens.

2. How has the market for NAVELBINE changed recently?
Revenues have declined steadily due to patent expirations and increased generic competition.

3. What are the prospects for NAVELBINE’s future sales?
Sales are expected to decline gradually with potential stabilization as it remains used in specific niches and emerging markets.

4. Are there any new formulations or indications in development?
No significant new formulations or indications are currently progressing through regulatory approval.

5. What factors could influence NAVELBINE’s market position?
Introduction of new targeted or immunotherapy agents, regulatory actions, and pricing pressures from generics.

References

[1] Grand View Research. (2022). Oncology Drugs Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Oncology Market Insights.